Released Aug 11, 2023, after the close
10-Q filed Aug 11, 2023, 42 days after period end · 0000950170-23-041851
Q2 2023 · 10-Q
Revenue—
Net Income-$1.45M-$1.45M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$5.83-$5.83 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$1,933,030N/M
Operating Cash Flowderived-$1,991,615N/M
Free Cash Flowderived-$1,991,615—
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$1.45M | -$1.83M | -$2.47M | -$521.00 |
| EPS Diluted | -$5.83 | -$4.16 | -$0.39 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR